Abstract-Accurate glycemic control (AGC) is difficult due to excessive hypoglycemia risk. Stochastic TARgeted (STAR) glycemic control forecasts changes in insulin sensitivity to calculate a range of glycemic outcomes for an insulin intervention, creating a risk framework to improve safety and performance. An improved, simplified STAR framework was developed to reduce light hypoglycemia and clinical effort, while improving nutrition rates and performance. Blood glucose (BG) levels are targeted to 80-145 mg/dL, using insulin and nutrition control for 1-3 h interventions. Insulin changes are limited to +3U/h and nutrition to ±30% of goal rate (minimum 30%). All targets and rate change limits are clinically specified and generalizable. Clinically validated virtual trials were run on using clinical data from 371 patients (39841 h) from the Specialized Relative Insulin and Nutrition Tables (SPRINT) cohort. Cohort and per-patient results are compared to clinical SPRINT data, and virtual trials of three published protocols. Performance was measured as time within glycemic bands, and safety by patients with severe (BG < 40 mg/dL) and mild (%BG < 72 mg/dL) hypoglycemia. Pilot trial results from the first ten patients (1486 h) are included to support the in-silico findings. In both virtual and clinical trials, mild hypoglycemia was below 2% versus 4% for SPRINT. Severe hypoglycemia was reduced from 14 (SPRINT) to 6 (STAR), and 0 in the pilot trial. AGC was tighter than both SPRINT clinical data and in-silico comparison protocols, with 91% BG within the specified target (80-145 mg/dL) in virtual trials and 89.4% in pilot trials. Clinical effort (measurements) was reduced from 16.2/day to 11.8/day (13.5/day in pilot trials). This STAR framework provides safe AGC with significant reductions in hypoglycemia and clinical effort due to stochastic forecasting of patient variation-a unique risk-based approach. Initial pilot trials validate the in-silico design methods and resulting protocol, all of which can be generalized to suit any given clinical environment.
proved difficult due to the associated risk of hypoglycemia when highly dynamic patients are treated with exogenous insulin [3] . Both extremes, as well as glycemic variability, have been independently linked to increased morbidity and mortality [4] [5] [6] , creating a difficult clinical problem safely and effectively regulating glycemia to a physiologically and clinically safe range.
Accurate glycemic control (AGC) can mitigate these outcomes [7] [8] [9] , but has proven difficult to achieve safely and consistently [10] [11] [12] . Only one study [8] reduced both mortality and hypoglycemia. However, the higher nursing workloads due to high-density glucose readings are impractical in many units [13] , [14] . Hand-held glucometers are easier for measurement, but their larger errors can add additional difficulty for some AGC protocols. Finally, clinical compliance determines much of the efficacy of any AGC method, with quality of glycemic control thus also limited by the confidence and compliance of nursing staff [14] , [15] . All of these issues interact with the inherent inter-and intra-patient metabolic variability [16] to exacerbate the difficulty of achieving good control. Hence, glycemic control targets have been raised to mitigate these factors and avoid hypoglycemia [17] , as a best outcome compromise, despite the physiological and clinical evidence on the negative impact of even moderate hyperglycemia [1] , [2] , [18] .
Directly quantifying and managing hyperglycemic and hypoglycemic risk as a function of inter-and intra-patient metabolic variability can leverage AGC benefits and minimize risk of unintended harm. Stochastic TARgeted (STAR) is a model-based AGC framework that can be implemented across a range of clinical scenarios and approaches, and uses dynamic and stochastic models to regulate blood glucose (BG) levels, workload, and patient safety within a predefined risk management approach. STAR uses stochastic forecasting of a patient's potential metabolic variability [19] in conjunction with a clinically validated mathematical model [20] to determine optimal insulin and nutrition treatment combinations with specified risks of moderate hyper-and hypo-glycemia. In essence, it is a patientspecific approach to manage inter-and intra-patient variability that overlaps the glycemic outcome range for a given intervention with a clinically specified desired glycemic range. It thus provides both control and a clinically specified risk of mild hypoglycemia. Hence, STAR provides a framework of models and methods to manage intra-and inter-patient variability to mitigate the significant difficulty and risk seen in current glycemic control approaches [3] , [16] .
Prior work in this field has led to the development of the individual components used in the STAR framework, and a preliminary STAR algorithm [21] . This paper presents an enhanced and simplified STAR protocol, including pilot trial results and a protocol comparison against four other published protocols. Specific focus is placed on reducing mild hypoglycemia (BG < 72 mg/dL) and its associated risk [4] , while maintaining 0018-9294/$31.00 © 2012 IEEE (6) glycemia in bands with the best evidence for improved outcome. Protocol simplicity and transparency are optimized to increase compliance, which can have a major impact on results [15] , [22] , signifying the importance of this work. As a result, and based on the results presented here, this optimized protocol has been adopted as the standard of care by Christchurch Hospital Intensive Care Unit (ICU).
II. METHODS

A. Model
The clinically validated Intensive Care Insulin-NutritionGlucose (ICING) metabolic model was used to simulate the fundamental metabolic dynamics [20] . Table I lists the population constants of the model defined in (1)- (6) , and a graphical overview is presented in Fig. 1 
u en = max 16.67,
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B. Virtual Patients
Clinically validated virtual trials [23] were carried out using the Specialized Relative Insulin and Nutrition Tables (SPRINT) AGC cohort clinical data [8] (371 patients, 39 841 h, 26 646 measurements) to create virtual patients. Virtual patients are created using clinical data to identify an hourly treatment-independent insulin sensitivity profile S I (t) [24] , allowing virtual trials to realistically simulate patient response to a given (modified) treatment. This approach has been clinically validated on independent matched cohort data [23] . Patient demographics are given in Table II. Patients were considered to require AGC once BG > 7.0 mmol/L, and this value was used to determine the beginning of a virtual trial. Interruptions in nutrition are common for some patients in clinical practice, and are incorporated by setting P (t) = 0 mmol/min over the same periods they occurred in the clinical data. Equally, clinically specified parenteral nutrition was included in the simulations just as it was given clinically.
C. Clinical Inputs
Insulin is administered in bolus form for safety from unintended delays [25] . However, infusions may also be used, if desired. Robustness to glucometer measurement error limits increases in insulin rate to +2 U/h, with upper limits on the total bolus dose each hour (6 U) and any added infusion rate for highly resistant patients (3 U/h). Thus, total insulin is limited to 9 U/h. No limit is placed on insulin reductions. Enteral nutrition is controlled between 30% and 100% of ACCP goal [26] , and changes are limited to ±30% per intervention cycle. However, nutrition administration can be set to a fixed constant rate or zero if clinically specified. For clinical applicability, insulin and nutrition are discretized to 0.5 U and 5% increments, respectively.
D. Stochastic Control Method
STAR provides patient-specific treatment in real time. Stochastic forecasting provides a framework for control of future outcomes, particularly the mitigation of mild, moderate, and severe hypoglycemia. STAR was also developed with the intent to use the simplest, most transparent control logic [15] . This latter aspect had the goal of ensuring its choices were as understandable as possible, and thus directly translated into safe, effective, and clinically acceptable treatment recommendations to maximize compliance. STAR maximizes performance (time in glycemic bands) with a minimum, clinically specified risk of mild hypoglycemia (5% for BG < 80 mg/dL, ≈1% for BG < 72 mg/dL). When a BG measurement is entered, integral-based fitting is used to identify the current insulin sensitivity parameter from the ICING model [24] , and a stochastic model is used to generate a range of insulin sensitivity values to use for prediction over the next 1-3 h. Stochastic models are generated a priori using a kernel density method [19] . The predicted insulin sensitivities are then used in conjunction with the ICING model to generate BG outcomes for potential insulin/nutrition combinations, and the treatment corresponding to the optimal outcome is selected. Optimal outcomes balance clinical workload, nutrition rates, and BG variability. Specifically, insulin cannot be administered if it poses a significant risk of hypoglycemia.
Once integral-based parameter fitting is used to identify insulin sensitivity over the last hour, simulation of the range of BG outcomes for each insulin/nutrition combination begins. Starting from the target nutrition rate and stepping down, fifth percentile (see Fig. 2 , points A-C) and 95th percentile BG outcomes (see Fig. 2 , points D-F) are simulated for every allowable insulin rate. For the current implemented form, typical runtime is approximately 15 s for up to 180 predictions. Importance is placed on maximizing nutrition rates [27] , particularly for longer stay patients, but not at the risk of exacerbating hyperglycemia.
For each insulin rate at a specific nutrition rate, if the onehourly fifth percentile BG outcome is below the target range, the combination is discarded and the algorithm moves on. Otherwise, if the prediction is in tolerance (see Fig. 3, panel A) , the combination is saved (but does not overwrite if a previous combination is already saved). Finally, if the prediction is not in tolerance, but is closer to the lower bound than any previous combinations, it is saved as a possible treatment. The treatment for the first hour does not use the full set of admissibility rules in Fig. 3 , as a treatment is required to exist at all times. If no insulin/nutrition combination corresponds to a fifth percentile BG outcome above the lower bound of the target range for 1 h, the controller defaults to maximum nutrition and zero insulin.
A similar procedure occurs at 2 and 3 h, with admissibility determined by the heuristic rules described in Fig. 3 . If a treatment is admissible under Fig. 3 : Condition A, the treatment is saved, whereas if it meets Condition B, it is saved as a possible treatment. Possible treatments are not overridden, instead saved/cleared after all insulin rates are tested for a given nutrition rate. If no allowable treatments exist, these longer time periods cannot be offered. If an allowable treatment is found, the selected nutrition rate is used as a lower limit for shorter treatment intervals. This approach ensures treatment consistency across all intervention and measurement intervals to maximize transparency and clinical acceptance, and thus compliance [15] . Specifically, it ensures an intuitive combination of treatment options, where longer measurement intervals generally yield wider stochastic forecasting bounds and thus more conservative (lower insulin) treatment choices.
The fifth percentile target is prioritized for control (see Fig. 3 ) due to the skewed nature of the BG outcome distribution, as depicted in Fig. 2 , which ensures BG outcomes best overlap the lower (80-125 mg/dL) desired portion of the 80-145 mg/dL range. This 80-125 mg/dL range is associated with better outcomes [5] , [9] and is also associated with reduced rate and severity of organ failure [28] . Tightness of the AGC provided by STAR is further ensured by the treatment of the 95th percentile forecast outcomes. Monitoring the likelihood of BG rising above the target range allows for more explicit direct control over intrapatient variability and therefore directly limits the risk and occurrence of mild hyperglycemia.
Measurement or treatment interval is specifically limited when 1) the current measured BG is outside the specified target range of 80-145 mg/dL (one-hourly limits); or 2) the patient is unable to be fed (two-hourly maximum interval). Otherwise, when the current measured BG is within the clinically specified target range, STAR calculates intervention options (insulin and nutrition) for one-, two-, and three-hourly measurement intervals. In clinical application, nursing staff chose between the available intervention options, allowing workload to be selfmanaged. For the virtual trials, two STAR versions were separately tested, "STAR-Max" (longest available option always selected) and "STAR two-hourly" (two-hourly options selected whenever available). These two result sets give an indication of the tradeoff between clinical workload and performance/safety, and the two-hourly version allows for direct comparison between STAR and the precursor protocol, SPRINT.
E. Virtual Trials
Virtual trials were carried out to verify performance before clinical testing. Results were compared to clinical SPRINT data to demonstrate improvements in performance and safety over the currently utilized SPRINT protocol that successfully reduced mortality [8] and organ failure [28] . Three other published protocols: UNC [29] , Yale [30] and GluControl A [22] were simulated in virtual trials for comparison and context.
F. Analyses/Performance Metrics
Performance was defined as a percentage of BG within selected glycemic bands. Clinical effort is evaluated by BG measurement frequency as a surrogate [13] , [14] . Safety was defined as the incidence of severe (number patients with BG < 40 mg/dL) and mild (%BG < 72 mg/dL) hypoglycemia. All BG data were resampled hourly to provide a consistent time basis for comparison across protocols with different measurement and intervention intervals.
Finally, the virtual trial approach is further validated in comparison to results for the first ten patients (1486 h, demographic shown in Table III ) in initial STAR pilot clinical trials. All patients were treated for length of stay after informed consent was obtained. Approval for this study and use of the data was given by the Upper South A Ethics Committee (URA/10/09/069).
III. RESULTS Table IV shows that both versions of STAR reduce the number of cases of severe hypoglycemia and more than halve the measures of mild hypoglycemia compared to SPRINT. There is a 79% reduction in severe hypoglycemia between STAR twohourly and SPRINT showing the importance of the STAR approach independent of measurement interval, as both protocols have a 2-h maximum interval and similar measurements per day. These safety gains are introduced with reduced clinical effort of 11.8 and 14.9 measures/day compared to 16.1 for SPRINT, and with equivalent or higher time in desired glycemic bands. Importantly, median nutrition rates are raised by 32% (absolute) of ACCP goal rate. Thus, all indications show that STAR will provide global improvements over SPRINT in performance, safety, and effort when applied clinically.
Figs. 4 and 5 display major behavioral differences between STAR and SPRINT. Each figure categorizes the insulin/nutrition combination selected to display relative frequency. Fig. 4 indicates that the preferred behavior of STAR is to modulate insulin at a higher nutrition rate, while Fig. 5 indicates that SPRINT typically modulates nutrition at moderate, relatively constant insulin administration levels. This difference implies a clinical advantage when high nutrition input is preferred. It equally highlights that insulin dosage behavior is relative to carbohydrate input, showing importance of accounting for nutrition in AGC, which many published protocols do not [31] . Finally, and equally importantly, the most common outcome in Fig. 4 is 100% goal feed and 0 U/h (11% of total interventions = 1 in 9), a safe and effective outcome enabled by the STAR framework's stochastic model-based approach that was not possible with SPRINT.
Global and per-patient statistics from virtual trials of the UNC, Yale, and GluControl A protocols are presented with STAR-Max and clinical SPRINT data in Table V . STAR compares favorably against all cases, providing tight control (lowest BG IQR) and safety (lowest incidence of severe hypoglycemia) with the least clinical effort (11.8 measures/day). The per-patient analysis in Table V indicates that the performance and safety benefits of STAR are realized over a wide range of heterogeneous patients. Safety against hypoglycemia, quantified by the median and IQR of %BG < 72 mg/dL, shows a significant reduction against both the clinical data and other AGC protocols. Median and IQR of the number of BG measures also indicate that the reduced clinical effort of STAR will be realized across patients.
The simulation results are supported by the initial pilot trial results presented in Table VI and Fig. 6 for the first ten patients with the target band of 80 (1486 h, 836 measurements). The clinical BG results are very similar to simulation results in Table IV with 
IV. DISCUSSION
STAR virtual trials demonstrate safe, effective AGC in a clinically applicable fashion. Significant safety improvements would be likely compared to the current generation of BG control in Christchurch Hospital (SPRINT), which was the safest published protocol targeting BG ≤ 110 mg/dL. Most significantly, only four patients out of 371 (1.1% by patient and a reduction of 71% from SPRINT) showed severe hypoglycemia, and, in all cases, this hypoglycemia was quickly resolved. Bulk cohort statistics were supported by the per-patient analysis as shown in Table IV , with STAR showing a more significant benefit than SPRINT and UNC, the next best protocol, for individual patient safety from hypoglycemia. Clinical applicability is strongly supported by the initial pilot results, with both the performance and safety benefits seen in virtual trials being realized in practice.
Characteristics of AGC varied between protocols. UNC showed improved performance over SPRINT, while providing a relatively light nursing workload. Safety was also improved with regards to mild hypoglycemia, although the incidence of severe hypoglycemia was increased. Although Yale showed improved safety, the number of required measurements was high.
STAR provided the tightest and safest control, while requiring the lowest nursing workload.
Importantly, all protocols showed relatively similar glycemic control in desired bands, and results not overly different from other clinical trials with ICU cohorts [3] . The main differentials are in mild (%BG < 72 mg/dL) and severe hypoglycemia (number of patients < 40 mg/dL). Equally, per-patient control, or consistency across interpatient variability, is better for SPRINT and STAR. These results match observations that those trials that have not succeeded in reducing mortality also had significantly increased hypoglycemia [3] , which is associated with worsened outcome [4] . Hence, the success of SPRINT [8] , [28] and the potential success of STAR rests on the (unique) ability to tightly control glycemia over a highly variable cohort and specific patients who have increased risk of hypoglycemia. Thus, the key differentiator, seen here in these virtual trial results, may lie with the ability to provide safe and tight glycemic control that is robust to significant inter-and intra-patient variability, which is what STAR was explicitly designed to achieve.
It should be noted that the target range of 80-145 mg/dL is based on the hypoglycemic risk (5%) being set on 80 mg/dL and the skewed outcome BG distribution that results from controlling hyperglycemia against a counter-regulatory response. As a result, controlled BG clusters in this range with outliers skewed toward higher values. Hence, while the range is 80-145 mg/dL, most BG values in Table IV are clustered in the 80-125 mg/dL range reflecting this skew. Thus, the lower target to 80 mg/dL helps ensure a tight range under control.
The insulin sensitivity parameter used here broadly represents the body's glycemic response to exogenous insulin under the ICING model assumptions. As such, mismodeled dynamics and/or sensor errors influence the fitted S I profile in an unphysiological manner. This is true for both virtual trials and real-time control. However, previous validation studies have shown that these profiles are essentially treatment independent [23] , and are therefore useful for conservative prediction of future outcomes. Validation of the virtual trial approach was carried out by testing the methodology on independent matched cohorts, where crossvalidation virtual trials accurately repeated clinical results from sliding scale protocols. Equally, the results here show that subsequent clinical trials are a good match for predicted response offering further validation.
The relatively higher enteral nutrition rate for STAR compared to SPRINT is likely to increase clinical acceptance. Higher feed is generally preferred in many cases [27] , despite some recent contradictory evidence [10] , [32] . However, STAR can be easily adjusted by setting nutrition administration goals to match any emerging evidence, and insulin rates will automatically modify to maintain glycemic balance.
The comparison between STAR-Max and STAR two-hourly illustrates a known tradeoff between measurement rate (nursing workload) and patient safety. However, both provide quality AGC. Thus, the main impact of measurement interval in the STAR framework is on safety from intrapatient variability.
Equally importantly, the ability of nursing staff to choose between measurement interval options means that an informed decision can be made at each BG reading. Thus, nurses selfmanage this workload. This choice or feature is expected to also have a positive impact on compliance and acceptance.
A notable enhancement of the model-based approach of STAR compared to the fixed approach in SPRINT is the ability to change the desired target range and other factors or limits. This ability has implications for the balance between workload, safety, and nutrition. For example, raising the target BG range could provide increased nutrition intake at the expense of higher BG. Providing a wider target band may allow reduced workload with fewer BG measurements under the target-torange scheme presented, but may result in increased glycemic variability within that band for which the clinical outcomes are not fully known. These decisions can be made by the attending clinical team based on their goals for a particular patient and assessment of current evidence. Hence, the framework can be directly and easily adopted and generalized to any clinical culture and practice, unlike previously published protocols.
More importantly perhaps, STAR can thus provide the power to automatically balance the clinical treatment, based on clinical goals for each patient. It thus avoids forcing a clinic-wide target or approach onto patients who have requirements outside the norm, or subjecting them to ad-hoc decisions to handle their particular cases. Thus, for example, different BG target ranges could be readily specified for different clinical conditions based on diagnosis and this target range could be updated as treatment progresses.
V. CONCLUSION
Achieving AGC requires accounting for patient metabolic variability while balancing safety and workload requirements. In-silico results indicate that the developed STAR algorithm provides a safe and effective method for management of glycemia. Both overall cohort and per-patient findings support the implementation of STAR in pilot clinical trials whose initial results have further validated the in-silico approach in this research. The model-based nature of STAR allows easy adjustment of BG and nutrition to match emerging clinical evidence, and permits individualization of treatment goals to particular patient outcomes. Finally, the overall framework presented is unique in its stochastic, risk-based approach, as well as completely generalizable.
